Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.3825
-0.0081 (-2.06%)
Aug 8, 2025, 4:00 PM EDT - Market closed
Vaxart Employees
Vaxart had 105 employees as of December 31, 2024. The number of employees decreased by 4 or -3.67% compared to the previous year.
Employees
105
Change (1Y)
-4
Growth (1Y)
-3.67%
Revenue / Employee
$451,381
Profits / Employee
-$553,543
Market Cap
87.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 105 | -4 | -3.67% |
| Dec 31, 2023 | 109 | -55 | -33.54% |
| Dec 31, 2022 | 164 | 54 | 49.09% |
| Dec 31, 2021 | 110 | 82 | 292.86% |
| Dec 31, 2020 | 28 | 14 | 100.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VXRT News
- 16 days ago - Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq - GlobeNewsWire
- 2 months ago - Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - GlobeNewsWire
- 2 months ago - Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewsWire
- 2 months ago - Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - GlobeNewsWire
- 2 months ago - Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewsWire
- 2 months ago - Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewsWire